The Prenylation Inhibitor, Lonafarnib: A New Therapeutic Strategy Against Hepatitis Delta

The Lancet Infectious Diseases - United Kingdom
doi 10.1016/s1473-3099(15)00155-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

In Vivo Antiviral Efficacy of Prenylation Inhibitors Against Hepatitis Delta Virus

Journal of Clinical Investigation
Medicine
2003English

In Vivo Antiviral Efficacy of Prenylation Inhibitors Against Hepatitis Delta Virus

Journal of Clinical Investigation
Medicine
2003English

RNAi, a New Therapeutic Strategy Against Viral Infection

Cell Research
Cell BiologyMolecular Biology
2004English

Optimizing Lonafarnib Treatment for the Management of Chronic Delta Hepatitis: The Lowr HDV - 1 Study

Hepatology
MedicineHepatology
2018English

E-Therapy as a Therapeutic Strategy Against Adolescent Obesity

ARC Journal of Pediatrics
2015English

Delta Hepatitis

Reviews in Health Care
2012English

Hepatitis Delta

2020English

MicroRNA: A New Therapeutic Strategy for Cardiovascular Diseases

Trends in Cardiovascular Medicine
Cardiovascular MedicineCardiology
2016English

Delta-Interacting Protein a and the Origin of Hepatitis Delta Antigen

Science
MultidisciplinaryPhilosophy of ScienceHistory
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy